Principal Financial Group’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-118,090
| Closed | -$2.82M | – | 2699 |
|
|
2021
Q1 | $2.82M | Buy |
118,090
+4,559
| +4% | +$84.7K | ﹤0.01% | 1792 |
|
|
2020
Q4 | $1.66M | Sell |
113,531
-10,144
| -8% | -$134K | ﹤0.01% | 1841 |
|
|
2020
Q3 | $1.76M | Buy |
123,675
+46,518
| +60% | +$711K | ﹤0.01% | 1757 |
|
|
2020
Q2 | $1.14M | Buy |
+77,157
| New | +$784K | ﹤0.01% | 1811 |
|
|
2018
Q4 | – | Sell |
-10,735
| Closed | -$79K | – | 2354 |
|
|
2018
Q3 | $79K | Buy |
+10,735
| New | +$78.8K | ﹤0.01% | 2241 |
|
|
2015
Q2 | – | Sell |
-12,264
| Closed | -$159K | – | 2232 |
|
|
2015
Q1 | $159K | Buy |
+12,264
| New | +$160K | ﹤0.01% | 2056 |
|
|
2014
Q4 | – | Sell |
-13,862
| Closed | -$124K | – | 2237 |
|
|
2014
Q3 | $124K | Buy |
+13,862
| New | +$149K | ﹤0.01% | 2117 |
|
|
2014
Q2 | – | Sell |
-18,075
| Closed | -$180K | – | 2334 |
|
|
2014
Q1 | $180K | Sell |
18,075
-81
| -0.4% | -$1.01K | ﹤0.01% | 2155 |
|
|
2013
Q4 | $242K | Buy |
+18,156
| New | +$220K | ﹤0.01% | 2084 |
|
|
2013
Q3 | – | Sell |
-15,138
| Closed | -$157K | – | 2305 |
|
|
2013
Q2 | $157K | Buy |
+15,138
| New | +$209K | ﹤0.01% | 2133 |
|
Principal Financial Group's GNMK Position: Q2 2021 in Review
Principal Financial Group sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 118,090 shares — an estimated $2.82M sold.
Principal Financial Group first reported a position in GNMK in Q2 2013 and held it in 10 quarters. The position peaked at $2.82M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Principal Financial Group reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Principal Financial Group sold 118,090 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $2.82M.
- Principal Financial Group first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 10 quarters.
- Principal Financial Group's GenMark Diagnostics, Inc position peaked at $2.82M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Principal Financial Group's 13F filing for Q2 2021, filed 10 Aug 2021.